Identification of colorectal cancer progression-associated intestinal microbiome and predictive signature constructionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study sought gut bacteria tied to colorectal cancer (CRC) progression and aimed to build stool-based signatures for staging. It compared early and advanced disease. Preoperative stool underwent 16S rDNA gene sequencing targeting the V3-V4 region. Tumor tissue from a subset had transcriptome sequencing. LEfSe found stage-linked bacteria, and correlations linked them to the tumor immune microenvironment. XGBoost and random forest models were built for staging prediction.
Who was studied?
The cohort was 192 CRC patients treated at a single hospital in Nanning, China, all with a defined TNM stage. Stools were collected before any treatment. Patients split into 62 with stage I-II (early) and 130 with stage III-IV (advanced). None had prior anti-tumor therapy or recent antibiotics. Tumor RNA sequencing used 17 CRC tissue samples. The study had no healthy-control arm, which the authors flag as a limitation.
What were the most important findings?
The Simpson index was significantly lower in stage III-IV than stage I-II (p equals 0.043), indicating higher diversity in advanced disease. LEfSe found 41 bacteria differing between stages. Proteus, Parabacteroides, Alistipes, and Ruminococcus were enriched in advanced tumors, while probiotics were dominant in early disease. Alistipes indistinctus rose at the species level with stage. Alistipes indistinctus correlated positively with mast cells and with IL-6 and IL6R, and with endoplasmic reticulum protein folding. A random forest model from 42 bacteria reached validation ROC-AUC of 0.729, outperforming XGBoost.
What are the greatest implications of this study?
The findings suggest gut microbial diversity and specific enriched genera rise as colorectal cancer advances. This supports stool bacteria as non-invasive markers for staging. Proposed mechanisms include Alistipes indistinctus boosting IL-6 to mature mast cells and easing endoplasmic reticulum stress via the unfolded protein response. These remain hypotheses drawn from correlations. The single-center design and absence of healthy controls limit conclusions. The authors call for larger, multi-center, and experimental validation.